Division of Cardiology had important participation at European Society of Cardiology congress in Paris
In the beginning of September, 2019, the cardiology team of School of Medical Sciences (SMC) of University of Campinas (Unicamp) attended to the landmark European Society of Cardiology (ESC) congress held in Paris, France. This congress is the World Congress of Cardiology as well and it is, undoubtedly, the biggest cardiology congress in the world with more than 32.000 cardiologists attending.
This year our cardiology team attending the congress – Daniel Munhoz, Daniel Mello, Thiago Quinaglia, Márcio Figueiredo, Otávio Coelho Filho and Otávio Coelho – witnessed the presentation of remarkable trials that will change cardiology practice in many aspects. The trials included a brand new drug to treat Heart Failure and new concepts to diagnose and treat Acute Coronary Syndromes, as well as new light as to interventional treatment of residual coronary obstructions after a Myocardial Infarction.
As for the important exchange of knowledge present in congress we had one of our internal medicine resident, Elayne Oliveira, presenting two clinical cases of our Clinics Hospital at Unicamp about constrictive pericarditis tuberculosis and beta 2 adrenergic receptor agonist induced myocarditis. She also presented a poster featuring a research led by Prof. Andrei Sposito about neuronal nitric synthetase in the context of ST elevation myocardial infarction. Elayne received a grant, directly from ESC to attend the congress. Thiago Quinaglia also presented a poster on the effect of cancer drugs anthracyclines on right ventricular function.
Dapagliflozin, a drug already in use for Diabetes Mellitus, proved useful In Heart Failure of reduced ejection fraction. This finding changed the tone of the congress, since Sacubitril/Valsartan did not show benefit in patients with Heart Failure with preserved ejection fraction in the PARAGON trial and the DAPA-HF trial saved the congress to be a let down in the cardiology field. Many other landmark trials were presented, including a surprising head to head comparison of ticagrelor and prasugrel.
Cardiologists have now plenty of information to analyse after this outstanding congress. Many information will help on the daily decisions of patients at Clinics Hospital of Unicamp, such as the benefit without increased risk of bleeding of monotherapy with rivaroxaban in patients with chronic coronary artery disease. New guidelines in pulmonary thromboembolism, diabetes, chronic coronary syndromes, tachyarrhythmias and dyslipidemia will be readily applied by our cardiology team at the hospital.